Spire Wealth Management’s AnaptysBio ANAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$60.3K Hold
1,200
– – ﹤0.01% 1090
2026
Q2
$81K Buy
1,200
+800
+200% +$48.5K ﹤0.01% 1038
2026
Q1
$22.2K Buy
+400
New +$21.5K ﹤0.01% 1390
2022
Q4
– Sell
-130
Closed -$3K – 2302
2022
Q3
$3K Hold
130
– – ﹤0.01% 1845
2022
Q2
$3K Hold
130
– – ﹤0.01% 2242
2022
Q1
$3K Hold
130
– – ﹤0.01% 2312
2021
Q4
$5K Buy
+130
New +$4.12K ﹤0.01% 2545

Other funds holding ANAB

Spire Wealth Management's ANAB Position: Q3 2026 in Review

Spire Wealth Management held its AnaptysBio (ANAB) position steady in Q3 2026 at 1,200 shares worth $60.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1090.

Spire Wealth Management first reported a position in ANAB in Q4 2021 and has held it in 7 quarters since. The position peaked at $81K in Q2 2026. 229 funds tracked by Wall St. Rank hold ANAB as of Q3 2026.

  • Spire Wealth Management held 1,200 shares of AnaptysBio worth $60.3K as of Q3 2026.
  • Spire Wealth Management left its AnaptysBio share count unchanged in Q3 2026.
  • AnaptysBio made up ﹤0.01% of Spire Wealth Management's portfolio in Q3 2026, its #1090 holding.
  • Spire Wealth Management first reported a position in AnaptysBio in Q4 2021 and has held it in 7 quarters since.
  • Spire Wealth Management's AnaptysBio position peaked at $81K in Q2 2026.
  • 229 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2026.

Based on Spire Wealth Management's 13F filing for Q3 2026, filed 30 Oct 2026.